Notice of Proposed Sale · 144
Alkermes plc
ALKSNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- Alkermes plc.
- Issuer CIK
- 0001520262
- SEC file number
- 001-35299
- Phone
- 00-353-1-772-8000
- Person for whose account securities are to be sold
- Nichols Christian Todd
- Relationships to issuer
- Officer
- Street
- CONNAUGHT HOUSE
- Street (continued)
- 1 BURLINGTON ROAD
- City
- DUBLIN 4
- State / country code
- L2
- Postal code
- 00000
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common Stock | 7,576 | 372,936.86 | 166,649,934 | 08/17/2026 | NASDAQ | Merrill Lynch |
Broker / market maker — proposed row 1, entry 1
- Name
- Merrill Lynch
- Street
- 225 Liberty Street
- Street (continued)
- Floor 37
- City
- New York
- State / country code
- NY
- Postal code
- 10281
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common Stock | 02/23/2025 | Vesting of restricted stock unit awards | Alkermes plc. | 2,473 | N | 02/23/2025 | Granted as part of issuer equity compensation plan |
| Common Stock | 02/22/2025 | Vesting of restricted stock unit awards | Alkermes plc. | 3,952 | N | 02/22/2025 | Granted as part of issuer equity compensation plan |
| Common Stock | 02/18/2025 | Vesting of restricted stock unit awards | Alkermes plc. | 1,151 | N | 02/18/2025 | Granted as part of issuer equity compensation plan |
Prior-sale reporting
- Nothing to report for the preceding three months
- Y
Notice signature
- Notice date
- 08/17/2026
- Signed
- Christian Nichols
- Plan adoption dates
- 11/19/2025
Company context
Alkermes plc (Nasdaq: ALKS), a mid-cap growth and value equity, is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Alkermes’ pipeline includes late-stage clinical candidates in development for narcolepsy and idiopathic hypersomnia, and orexin 2 receptor agonists in early clinical development for other neurological disorders, including attention-deficit hyperactivity disorder (ADHD) and fatigue associated with multiple sclerosis and Parkinson’s disease. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes’ website at www.alkermes.com.
Current securities
Recent company filings
- Regulation FD Disclosure · Other EventsSep 21, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD DisclosureSep 16, 2026
- 144 filingSep 3, 2026
- 144 filingSep 1, 2026
- Entry into a Material Definitive AgreementAug 12, 2026